Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
Not much to say: I am a retiree who can at last be an almost full time investor, not quite a day trader but a short term trader. Not because I think that this will make me richer as a "real" investor, that keeps it's long positions for months or even years! It's just more fun.
A new position per day is healthy :-)
I live in Canada, and the TSX contains a terrible percentage of stocks that pollute and/or endangers the native population's health (mining, oil sand), I never buy them but wait till some of those are ready to short. And then yes I am happy.
Am I too pessimistic? I always do better when I short.
But this does not mean that I am only a shorter, not at all.
Very conservative with my RSSP, I love to risk a little more with two other not too rich accounts, one of them being in USD.
Trading is not my only "hobby", I am a pretty good dressage rider, and I love gardening and caring for older persons.
And as you can see, I love to write, even if English is only my third language.
I am a paramedic. I am not an analyst, I am not a financial adviser, I cannot predict the future, nor am I privy to any insider information. My only intention is to provide retail investors with the science and to clear up some of the misinformation spread by everyone with internet access.
Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the equity research company "BNL Finance". An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
George Albert is the Founder of Swarnam Capital and Editor of www.capturetrends.com. Swarnam Capital invests in real estate, index futures and the foreign currency markets. As editor of Capturetrends, George's are published in Seeking Alpha, International Business Times (ibtimes.com), Morningstar (morningstar.com), Trader Planet in the US as well as in India in publications such as Business Standard, Smart Investor, First Post, DNA India and Financial Express. He also teaches trading and investing at Harper College, Chicago